Locations:
SearchAdvertisement
Reducing risk of recurrence 70%
Reduces muscle pain caused by cholesterol-lowering drugs
Reduces incidence of infection by 40% compared to standard of care
Romosozumab builds more bone than any previous medication
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
FDA makes MitraClip available to more patients with mitral regurgitation
Tafamidis is first FDA-approved drug to treat potentially fatal disease
Oral immunotherapy drug is first of its kind
Technology adjusts dose of stimulation to help optimize pain control
Seeking better long-term results after ACL and rotator cuff injuries
Advertisement
Advertisement